Trend-Following Backtester · Guide · backtest 한국어

equity · IN

Sun Pharmaceutical Industries Limited backtest

10 trend-following strategies were compared on the full daily history of Sun Pharmaceutical Industries Limited. 0 beat buy-and-hold CAGR; EMA 크로스오버 ranks first by Sharpe, matching the main backtester.

Data 1996-01-01 ~ 2026-07-31daily bars 7,679 (30.6 years)Costs 0.5%Venue NSEMonthly snapshot 2026-07-31

Results by strategy

0 of 10 beat buy and hold (CAGR 25.7%, drawdown -72.2%).

Sharpe leader (same as main): EMA 크로스오버 — CAGR 23.5%, MDD -66.1%, Sharpe 0.82, 77% exposure.

No strategy retained at least 75% of buy-and-hold CAGR while reducing drawdown by both 20% relatively and 5 percentage points absolutely.

The alternative must retain 75% of buy-and-hold CAGR, improve drawdown by at least 20% and 5 percentage points, and stay below 95% exposure; the ranking weights return retention 60% and drawdown improvement 40%.

Strategy · parametersCAGRMDDSharpeCalmarTotalTradesExposure
EMA 크로스오버
fast=21, slow=401
23.5%-66.1%0.820.36637.3x2577%
Donchian 채널 돌파
entryN=7, exitN=51
22.0%-63.1%0.770.35435.6x9789%
SMA 크로스오버
fast=58, slow=213
18.6%-69.8%0.720.27186.1x3571%
Keltner 채널 돌파
emaPeriod=169, atrPeriod=25, mult=3.3
13.7%-56.5%0.630.2450.7x5355%
ROC 모멘텀
n=143, threshold=0.02
13.1%-76.3%0.570.1743.1x24170%
MACD
fast=16, slow=52, signal=18
9.6%-47.3%0.490.2016.6x32951%
볼린저 밴드 돌파
n=74, k=1.5
9.1%-53.4%0.470.1714.4x12949%
Supertrend
period=11, mult=4
9.4%-67.4%0.460.1415.5x11763%
Parabolic SAR
step=0.015, maxStep=0.18
5.9%-74.6%0.350.085.8x53154%
ADX / DI 방향성
period=34, threshold=11
2.4%-79.8%0.220.032.1x30949%
Buy and hold25.7%-72.2%0.820.361098.1x1100%
1x 10x 100x 1,000x 1997 2001 2005 2009 2013 2017 2021 2025 EMA 크로스오버Buy and hold
EMA 크로스오버: Solid strategy line versus dashed buy-and-hold line. Log scale.
0% -18% -36% -54% -72% 1997 2001 2005 2009 2013 2017 2021 2025 Buy and holdEMA 크로스오버
EMA 크로스오버 maximum drawdown -66.1% (2000-02-28 → 2000-05-02), recovered after 1,345 days.

Rules of the top strategy

Uses two exponential averages (more weight on recent prices) and trades their crossover.

Method and caveats

Past performance does not guarantee future returns. Parameters were selected on the same full-history sample using sharpe over 40 trials per strategy, so results contain in-sample bias. 0.5% trading costs are included; taxes, slippage and rejected orders are not.
Re-run the same setupAll asset reports

Read next